This company has been marked as potentially delisted and may not be actively trading. NASDAQ:JUNS Jupiter Neurosciences (JUNS) Stock Price, News & Analysis Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsCompetitorsEarningsHeadlinesInsider TradesTrendsBuy This Stock About Jupiter Neurosciences Stock (NASDAQ:JUNS) 30 days 90 days 365 days Advanced Chart Get Jupiter Neurosciences alerts:Sign Up Key Stats Today's Range$1.21▼$1.8950-Day Range N/A52-Week Range N/AVolume4.93 million shsAverage Volume1.03 million shsMarket Capitalization$54.62 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingStrong Buy Company Overview Jupiter Neurosciences, Inc., a clinical stage research and development pharmaceutical company, develops resveratrol platform product primarily for the treatment of neuro-inflammation. It is developing JNS101 that is in Phase II trials for the treatment of Friedreich's Ataxia, a rare disease that causes damage to the nervous system, as well as mobility dysfunctions; and JNS102, which is in Phase II trials for the treatment of mucopolysaccharidosis Type I. The company is also developing JNS107 that is in Phase II trials for the treatment of MELAS Syndrome; and JNS108, which is in Phase II trials for the treatment of mild cognitive impairment/early Alzheimer's disease. In addition, it is developing JNS109 for amyotrophic lateral sclerosis; JNS110 for traumatic brain injury/concussion; and JNS120 for covid-19 treatment. The company was formerly known as Jupiter Orphan Therapeutics, Inc. and changed its name to Jupiter Neurosciences, Inc. in August 2021. The company was founded in 2016 and is headquartered in Jupiter, Florida. Read More Receive JUNS Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Jupiter Neurosciences and its competitors with MarketBeat's FREE daily newsletter. Email Address JUNS Stock News HeadlinesJupiter Neurosciences Showcases Nugevia™ PWR: Mitochondrial Optimization Supplement Designed to Boost Energy, Endurance, and Recovery - MorningstarJuly 2, 2025 | morningstar.comMJupiter Neurosciences to launch mitochondrial health supplement this fallJuly 2, 2025 | investing.comTrump’s treachery Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to move your money now.July 6 at 2:00 AM | Porter & Company (Ad)Jupiter Neurosciences Showcases Nugevia™ PWR: Mitochondrial Optimization Supplement Designed to Boost Energy, Endurance, and RecoveryJune 30, 2025 | globenewswire.comJupiter Neurosciences Unveils Nugevia™ GLO: A Breakthrough in Cellular Skin Health, Backed by Patented Pharmaceutical ScienceJune 27, 2025 | finance.yahoo.comJupiter Neurosciences Appoints Annika Sörenstam as First Brand Ambassador for Nugevia™ Longevity Supplement Line - NasdaqJune 25, 2025 | nasdaq.comJupiter Neurosciences Names Golf Legend Annika Sörenstam as First Nugevia™ Brand AmbassadorJune 23, 2025 | globenewswire.comJupiter Neurosciences, Inc.: Jupiter Neurosciences Launches Nugevia: A Premium Longevity and Performance Supplement Line Grounded in Clinical ScienceJune 10, 2025 | finanznachrichten.deSee More Headlines JUNS Stock Analysis - Frequently Asked Questions How were Jupiter Neurosciences' earnings last quarter? Jupiter Neurosciences, Inc. (NASDAQ:JUNS) posted its quarterly earnings data on Thursday, May, 15th. The company reported ($0.05) earnings per share for the quarter, missing the consensus estimate of ($0.03) by $0.02. When did Jupiter Neurosciences IPO? Jupiter Neurosciences (JUNS) raised $11 million in an initial public offering on Tuesday, December 3rd 2024. The company issued 2,800,000 shares at a price of $4.00 per share. Dominari Securities and Revere Securities acted as the underwriters for the IPO. When did the company's lock-up period expire? Jupiter Neurosciences's lock-up period expired on Monday, June 2nd. Jupiter Neurosciences had issued 2,750,000 shares in its public offering on December 3rd. The total size of the offering was $11,000,000 based on an initial share price of $4.00. Since the expiration of the company's lock-up period, restrictions preventing company insiders and major shareholders from selling shares in the company have been lifted. Company Calendar Last Earnings5/15/2025Today7/06/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED-DRUGS Sub-IndustryN/A Current SymbolNASDAQ:JUNS CIK1679628 Webwww.jupiterorphan.com Phone561 406 6154FaxN/AEmployees5Year FoundedN/AProfitability EPS (Trailing Twelve Months)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current Ratio1.91 Quick Ratio1.91 Sales & Book Value Annual Sales$230 thousand Price / Sales237.46 Cash FlowN/A Price / Cash FlowN/A Book Value$0.13 per share Price / Book12.69Miscellaneous Outstanding Shares33,100,000Free FloatN/AMarket Cap$54.62 million OptionableNot Optionable BetaN/A 13 Stocks Institutional Investors Won't Stop BuyingWhich stocks are hedge funds and endowments buying in today's market? Enter your email address and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying now.Get This Free Report This page (NASDAQ:JUNS) was last updated on 7/6/2025 by MarketBeat.com Staff From Our PartnersINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | Sponsored140% Yields From Stocks Like Tesla? Here's How (July 4th Special)Imagine getting a 140% dividend from your investments. Even better? It works with big names like Tesla, ...Investors Alley | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | SponsoredPresidential Bombshell: $150T Resource to Be Released as soon as this Summer?Something extraordinary is happening in Washington. For the first time in over a century, a sitting Preside...Paradigm Press | SponsoredThe day and month stocks are most likely to crash nextGood News for Stocks 50-year Wall Street veteran, Marc Chaikin is stepping forward to share why history giv...Chaikin Analytics | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredIs Elon's empire crumbling?The Tesla Shock Nobody Sees Coming While headlines scream "Tesla is doomed"... Jeff Brown has uncovered ...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Jupiter Neurosciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Jupiter Neurosciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.